The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...
The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
Novo Nordisk A/S’s Rybelsus diabetes pill, a tablet version of Ozempic, reduced the risk of heart attacks and strokes in a large study that may drive broader use of the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback